Monomethyl auristatin E (GMP)

Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor[1].

Product Specifications

CAS Number

[474645-27-7]

Product Name Alternative

MMAE (GMP) ; SGD-1010 (GMP) ; Vedotin (GMP)

UNSPSC

12352005

Hazard Statement

H300+H330, H340, H360, H370, H372, H412

Target

ADC Payload; Apoptosis; Microtubule/Tubulin

Type

GMP Small Molecules

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/monomethyl-auristatin-e-gmp.html

Purity

99.30

Solubility

Ethanol : 50 mg/mL (ultrasonic; warming)

Smiles

CC(C)[C@H](NC)C(N[C@@H](C(C)C)C(N(C)[C@H]([C@@H](CC(N1[C@]([C@H](OC)[C@H](C(N[C@@H]([C@H](C2=CC=CC=C2)O)C)=O)C)(CCC1)[H])=O)OC)[C@H](CC)C)=O)=O

Molecular Formula

C39H67N5O7

Molecular Weight

717.98

Precautions

H300+H330, H340, H360, H370, H372, H412

References & Citations

[1]Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16 (3), 888-897.|[2]Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75 (7) :1376-87.